T2 Biosystems, Inc.
NASDAQ:TTOO
0.8 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 7.193 | 22.305 | 28.058 | 18.13 | 8.335 | 10.5 | 4.666 | 4.08 | 2.813 | 0.119 | 0.266 | 0.019 |
| Cost of Revenue
| 16.022 | 21.139 | 20.703 | 21.28 | 16.763 | 15.404 | 12.028 | 6.872 | 1.74 | 19.782 | 14.936 | 11.727 |
| Gross Profit
| -8.829 | 1.166 | 7.355 | -3.15 | -8.428 | -4.904 | -7.362 | -2.792 | 1.073 | -19.663 | -14.67 | -11.708 |
| Gross Profit Ratio
| -1.227 | 0.052 | 0.262 | -0.174 | -1.011 | -0.467 | -1.578 | -0.684 | 0.381 | -165.235 | -55.15 | -616.211 |
| Reseach & Development Expenses
| 13.494 | 25.932 | 21.801 | 16.919 | 16.326 | 14.489 | 23.733 | 24.009 | 25.362 | 19.782 | 14.936 | 11.727 |
| General & Administrative Expenses
| 0 | 30.644 | 0 | 0 | 0 | 25.697 | 22.757 | 24.077 | 19.094 | 11.018 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 24.83 | 30.744 | 28.527 | 21.287 | 27.304 | 25.697 | 22.757 | 24.077 | 19.094 | 11.018 | 5.022 | 2.945 |
| Other Expenses
| -0.495 | 0.031 | 0.206 | 0.062 | 0.4 | 0.619 | 0.331 | 0.172 | 0.06 | 0.012 | -0.515 | 0.352 |
| Operating Expenses
| 38.324 | 56.676 | 50.328 | 38.206 | 43.63 | 40.186 | 46.49 | 48.086 | 44.456 | 30.8 | 19.958 | 14.672 |
| Operating Income
| -47.153 | -55.51 | -42.973 | -41.356 | -52.058 | -45.09 | -53.852 | -50.878 | -43.383 | -30.681 | -19.692 | -14.653 |
| Operating Income Ratio
| -6.555 | -2.489 | -1.532 | -2.281 | -6.246 | -4.294 | -11.541 | -12.47 | -15.422 | -257.824 | -74.03 | -771.211 |
| Total Other Income Expenses Net
| -2.924 | -6.807 | -6.268 | -5.442 | -6.948 | 0.619 | 0.331 | 0.172 | 0.06 | 0.012 | -0.515 | 0.352 |
| Income Before Tax
| -50.077 | -62.317 | -49.241 | -46.798 | -59.006 | -51.153 | -62.428 | -54.804 | -45.29 | -31.39 | -20.61 | -14.455 |
| Income Before Tax Ratio
| -6.962 | -2.794 | -1.755 | -2.581 | -7.079 | -4.872 | -13.379 | -13.432 | -16.1 | -263.782 | -77.481 | -760.789 |
| Income Tax Expense
| 0.691 | 1.053 | 4.254 | 2.41 | 4.106 | 0.619 | 9.238 | 1.99 | 0.562 | 0.042 | -0.112 | 0.506 |
| Net Income
| -50.077 | -63.37 | -53.495 | -49.208 | -63.112 | -51.153 | -62.428 | -54.804 | -45.29 | -31.39 | -20.61 | -14.455 |
| Net Income Ratio
| -6.962 | -2.841 | -1.907 | -2.714 | -7.572 | -4.872 | -13.379 | -13.432 | -16.1 | -263.782 | -77.481 | -760.789 |
| EPS
| -19.19 | -1,242.48 | -1,683.72 | -2,027.86 | -6,934.2 | -126.12 | -194.29 | -210.66 | -220.91 | -361.85 | -1,476.89 | -103.27 |
| EPS Diluted
| -19.19 | -1,242.48 | -1,683.72 | -2,027.86 | -6,934.2 | -126.12 | -194.29 | -210.66 | -220.91 | -361.85 | -1,476.89 | -103.27 |
| EBITDA
| -46.294 | -55.471 | -42.655 | -41.294 | -51.658 | -44.471 | -50.581 | -50.706 | -43.323 | -30.669 | -19.623 | -13.73 |
| EBITDA Ratio
| -6.436 | -2.487 | -1.52 | -2.278 | -6.198 | -4.235 | -10.84 | -12.428 | -15.401 | -257.723 | -73.771 | -722.632 |